Your browser doesn't support javascript.
loading
Stem Cell Therapy for Diabetic Foot Ulcers: Theory and Practice.
Nalisa, David Lubasi; Moneruzzaman, Md; Changwe, Geoffrey J; Mobet, Youchaou; Li, Li Ping; Ma, Yu Jin; Jiang, Hong Wei.
Affiliation
  • Nalisa DL; Department of Metabolism and Endocrinology, Endocrine and Metabolic Disease Center, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China 471003.
  • Moneruzzaman M; Medical Key Laboratory of Hereditary Rare Diseases of Henan, Luoyang, China 471003.
  • Changwe GJ; Luoyang Sub-Center of National Clinical Research Center for Metabolic Diseases, Luoyang, China 471003.
  • Mobet Y; Department of Rehabilitation Medicine and Physiotherapy, Qilu Hospital of Shandong University, Shandong University, Jinan, Shandong 250012, China.
  • Li LP; Department of Cardiovascular and Thoracic Surgery, National Heart Hospital, Off-Airport Road, 10101 Lusaka, Zambia.
  • Ma YJ; Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China.
  • Jiang HW; Department of Metabolism and Endocrinology, Endocrine and Metabolic Disease Center, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China 471003.
J Diabetes Res ; 2022: 6028743, 2022.
Article in En | MEDLINE | ID: mdl-36524153
Diabetic foot ulcers are associated with increases in limb amputation, morbidity, and mortality. Recently, a stem cell application is emerging as promising adjuvant therapy. We presented available remedies by conducting a literature review on the application, safety, and efficacy of stem cell therapy. Relevant literature, including randomized control trials and article journals, was obtained from reputable search engines (PubMed, Scopus, and Web of Science). We analyzed five credible cohorts, with variable sources of stem cells, in a total of 216 participants, 151 males and 65 females, age (mean ± SD) of 64.5 ± 9.6 years. With an average success of 86.41% in all Wagner-II lesions, mesenchymal SCA (stem cell application) is safe and effective, hence can significantly prevent limb amputation.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetic Foot / Diabetes Mellitus Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Diabetes Res Year: 2022 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetic Foot / Diabetes Mellitus Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Diabetes Res Year: 2022 Type: Article